A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Americans are flocking to new weight loss medications like Novo Nordisk’s Wegovy and Eli Lilly's Zepbound, which work by ...

Detailed price information for Restaurant Brands International (QSR-N) from The Globe and Mail including charting and trades.

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.